EHI
FDMT icon

Eagle Health Investments’s 4D Molecular Therapeutics FDMT Stock Holding History

Eagle Health Investments’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-462,911
Closed -$5M – 21
2024
Q3 		$5M Hold
462,911
– – 0.95% 18
2024
Q2 		$9.72M Hold
462,911
– – 1.7% 21
2024
Q1 		$14.7M Buy
462,911
+25,000
+6% +$638K 2.74% 13
2023
Q4 		$8.87M Hold
437,911
– – 1.8% 16
2023
Q3 		$5.57M Hold
437,911
– – 1.23% 20
2023
Q2 		$7.91M Hold
437,911
– – 1.48% 20
2023
Q1 		$7.53M Hold
437,911
– – 1.47% 19
2022
Q4 		$9.73M Buy
437,911
+69,500
+19% +$1.07M 2.24% 15
2022
Q3 		$2.96M Buy
368,411
+106,988
+41% +$969K 0.68% 22
2022
Q2 		$1.82M Buy
261,423
+129,333
+98% +$1.26M 0.43% 23
2022
Q1 		$2M Hold
132,090
– – 0.49% 22
2021
Q4 		$2.9M Buy
132,090
+75,000
+131% +$1.84M 0.71% 22
2021
Q3 		$1.54M Hold
57,090
– – 0.49% 25
2021
Q2 		$1.38M Buy
57,090
+7,090
+14% +$217K 0.47% 29
2021
Q1 		$2.17M Hold
50,000
– – 0.85% 24
2020
Q4 		$2.07M Buy
+50,000
New +$2.06M 1.33% 21

Other funds holding FDMT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Eagle Health Investments's FDMT Position: Q4 2024 in Review

Eagle Health Investments sold out of 4D Molecular Therapeutics (FDMT) in Q4 2024, closing a stake of 462,911 shares — an estimated $5M sold.

Eagle Health Investments first reported a position in FDMT in Q4 2020 and held it in 16 quarters. The position peaked at $14.7M in Q1 2024. 145 funds tracked by Wall St. Rank hold FDMT as of Q4 2024.

  • Eagle Health Investments reported no remaining 4D Molecular Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Eagle Health Investments sold 462,911 4D Molecular Therapeutics shares in Q4 2024, an estimated $5M.
  • Eagle Health Investments first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 16 quarters.
  • Eagle Health Investments's 4D Molecular Therapeutics position peaked at $14.7M in Q1 2024.
  • 145 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2024.

Based on Eagle Health Investments's 13F filing for Q4 2024, filed 12 Feb 2025.